Printer Friendly

CHICAGO BOARD TO LIST CYTRX OPTIONS

 CHICAGO BOARD TO LIST CYTRX OPTIONS
 NORCROSS, Ga., March 6 /PRNewswire/ -- CytRx Corporation


(NASDAQ: CYTR) announced today that the Chicago Board Options Exchange (CBOE) will begin trading options on CytRx Common Stock on Monday, March 9.
 CytRx options will trade on the March expiration cycle, with introductory expirations in March, April, June and September. Initial strike prices have been set at $7.50, $10.00 and $12.50. The CBOE ticker symbol for the CytRx options will be CTQ.
 CytRx Corporation is a biopharmaceutical company engaged in the research and development of therapeutics incorporating copolymers. The company is developing human pharmaceutical products intended for use in the treatment of vascular, immune system and infectious diseases as well as burns. The company is also developing feed additives intended for growth enhancement in food animals, adjuvants for use in both human and veterinary vaccines and is currently marketing Hunter's TiterMax(TM), an immunoadjuvant for use by the basic research community.
 -0- 3/6/92
 /CONTACT: CytRx Corporation public relations, 404-368-9500/
 (CYTR) CO: CytRx Corporation ST: Georgia IN: MTC SU:


BR-BN -- AT001 -- 5744 03/06/92 09:20 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 6, 1992
Words:186
Previous Article:SECOM GENERAL UPDATES POSITION REGARDING PARK-OHIO INDUSTRIES, INC.
Next Article:NATIONAL COMPUTER SYSTEMS APPOINTS NEW CHIEF FINANCIAL OFFICER
Topics:


Related Articles
CYTRX ANNOUNCES EXERCISE OF CLASS B WARRANTS
CYTRX CORPORATION ANNOUNCES TENDER OFFER FOR PREFERRED STOCK
CYTRX CORPORATION ANNOUNCES SUCCESSFUL COMPLETION OF PREFERRED STOCK TENDER OFFER
CYTRX ANNOUNCES PLANS TO REPURCHASE STOCK
CYTRX ANNOUNCES PLANS FOR REVERSE STOCK SPLIT
CytRx Corporation Announces Adoption of Shareholder Protection Rights Plan
CytRx Announces Private Placement of $2 Million in Convertible Debentures
CytRx Announces Achievement of Midpoint in FLOCOR Phase III Trial.
CytRx Announces Engagement of Cappello Capital; Alexander Cappello Joins CytRx Board.
CytRx Corporation Announces Merger With Global Genomics Capital, Inc.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters